Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accounts Payables (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Accounts Payables for 16 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 47.55% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2025, down 47.55% year-over-year, with the annual reading at $5.9 million for FY2025, 47.55% down from the prior year.
  • Accounts Payables for Q4 2025 was $5.9 million at Plus Therapeutics, down from $11.6 million in the prior quarter.
  • The five-year high for Accounts Payables was $11.6 million in Q3 2025, with the low at $1.6 million in Q2 2021.
  • Average Accounts Payables over 5 years is $6.2 million, with a median of $6.4 million recorded in 2025.
  • The sharpest move saw Accounts Payables plummeted 55.4% in 2021, then skyrocketed 226.85% in 2022.
  • Over 5 years, Accounts Payables stood at $2.6 million in 2021, then surged by 218.02% to $8.4 million in 2022, then plummeted by 43.11% to $4.8 million in 2023, then skyrocketed by 137.24% to $11.3 million in 2024, then crashed by 47.55% to $5.9 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $5.9 million, $11.6 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.